Turk Bengi Gül¹*, Asan Furkan², Zeynep Ece Kaya-Güleç³, Damla Çetinkaya-Tezer⁴ and Abdülsamet Çam⁵

¹Neurology Department, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey
²Neurology Department, Iğdir State Hospital, Iğdır, Turkey
³Neurology Department, Adiyaman Training and Research Hospital, Adıyaman, Turkey
⁴Neurology Department, Sancaktepe Training and Research Hospital, Istanbul, Turkey
⁵Neurology Department, Muş State Hospital, Muş, Turkey

*Corresponding Author: Bengi Gül Türk, Turk Bengi Gül, Neurology Department, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey

Received: July 11, 2021; Published: August 30, 2021

Abstract

Objectives and Background: Our study aims to evaluate the effect of the greater occipital nerve (GON) block on chronic migraine patients’ successful adaptation to prophylactic therapy.

Methods: We included 40 patients with CM. Patients were divided into two groups: group 1 (n = 20) consisted of patients who underwent GON block, and group 2 (n = 20) consisted of patients who did not receive GON block. All patients were followed up for three months. The endpoints of this study were the decrease in visual analog scale score, total number of painful days in a month and the compliance with treatment.

Results: At the end of the third month, the mean number of total painful days in a month was found to be significantly lower in group 1 as compared with group 2.

The mean visual analog scale score in the third month was found to be significantly lower in group 1 than in group 2.

After three months of follow-up, the rate of discontinuation of prophylactic treatment was significantly lower in group 1 than in group 2.

Conclusion: GON intervention has been shown to significantly reduce pain intensity and frequency in CM. The authors suggest that GON block provides an improvement in patient compliance with prophylactic therapy in CM.

Keywords: Chronic Migraine; Greater Occipital Nerve Block

References

1. Chaganti SS., et al. “What do we know about Late Onset Huntington’s Disease?” Journal of Huntington's Disease 2 (2017): 95-103.
2. Axisa PP and Hafler DA. “Multiple sclerosis: Genetics, biomarkers, treatments”. Current Opinion in Neurology3 (2016): 345-353.
3. Maloni HW and Wallin MT. “Presentation of multiple sclerosis with comorbid Huntington’s disease”. Clinical Neurology and Neurosurgery 136 (2015): 86-88.
4. Murphy R., et al. “Neuropsychiatric syndromes of multiple sclerosis”. Journal of Neurology, Neurosurgery and Psychiatry8 (2017): 697-708.
5. Snowden JS. “The Neuropsychology of Huntington’s Disease”. Archives of Clinical Neuropsychology7 (2017): 876-887.
6. Steenhof M., et al. “Familial multiple sclerosis patients have a shorter delay in diagnosis than sporadic cases”. Multiple Sclerosis and Related Disorders 32 (2019): 97-102.
7. Beecham AH., et al. “Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis”. Nature Genetics 45 (2013): 1353-1360.
8. Barragán-Martínez C., et al. “Organic Solvents as Risk Factor for Autoimmune Diseases: A Systematic Review and Meta-Analysis”. PLoS One12 (2012): e51506.
9. Gusella JF., et al. “Genetic modifiers of Huntington’s disease”. Movement Disorders 11 (2014): 1359-1365.
10. Thomson SB and Leavitt BR. “Transcriptional regulation of the huntingtin gene”. Journal of Huntington's Disease4 (2018): 289-296.

Citation

Citation: Turk Bengi Gül., et al. “The Importance of Greater Occipital Nerve Block for Compliance with Prophylaxis Treatment in Chronic Migraine Patients: A Randomized Controlled Trial". Acta Scientific Neurology 4.9 (2021): 72-76.

Copyright

Copyright: © 2021 Turk Bengi Gül., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.